A novel taxane improves progression-free and overall survival of patients with metastatic, hormone-refractory prostate cancer after failure of docetaxel therapy.
ASJC Scopus subject areas
Jana, B. R. P. (2010). Cabazitaxel and prednisone as second-line therapy of metastatic, castration-resistant prostate cancer. Community Oncology, 7(12), 540-542. https://doi.org/10.1016/s1548-5315(11)70531-9